Champions Oncology, Inc. cash flow to debt ratio of 120.98% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Champions Oncology, Inc.'s free cash flow has increased -200.34% from $-6.97M last year to $7.00M, signaling increasing performance

Champions Oncology, Inc.'s debt to equity ratio is 1.17, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Champions Oncology, Inc.'s debt has increased relative to shareholder equity from -3.90 last year to 1.17 today, signaling weakened financials

Champions Oncology, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Champions Oncology, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Champions Oncology, Inc.'s profit margin has increased (-72.86%) in the last year from -14.51% to -3.94%, signaling increasing performance

Champions Oncology, Inc.'s short-term liabilities of $23.85M exceed its short-term assets of $22.37M, signaling financial risk

Champions Oncology, Inc.'s return on assets of -8.02% is lower than the 5.00% threshold, indicating inefficient asset utilization

Champions Oncology, Inc.'s return on equity of -57.99%, is lower than 15.00%, indicating bad performance

Champions Oncology, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Champions Oncology, Inc. had positive net income in 3.00 out of 5 years, indicating stable and consistent earnings

Champions Oncology, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Champions Oncology, Inc. has a free cash flow yield of 7.60%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Champions Oncology, Inc.'s yearly earnings has increased -164.61% since last year from $-7.28M to $4.70M, signaling increasing performance

Champions Oncology, Inc.'s yearly revenue has increased 13.54% since last year from $50.16M to $56.94M, signaling increasing performance

ROIC -23.16% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Champions Oncology, Inc.'s 3-year revenue CAGR of 5.06% is positive, indicating growing revenue over the past 3 years

Champions Oncology, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Champions Oncology, Inc. had positive ROE in 3.00 out of 5 years, indicating consistent and reliable returns on equity

Champions Oncology, Inc. is undervalued relative to its fair value price of 9.21 based on Discounted Cash Flow model

Champions Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Champions Oncology, Inc. is overvalued relative to its fair value price of 3.44 based on EBITDA multiple model

Champions Oncology, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Champions Oncology, Inc. is overvalued relative to its fair value price of 0.82 based on Earnings Fair Value model

Champions Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Champions Oncology, Inc. has a price-to-book ratio of 21.50x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Champions Oncology, Inc. has a price-to-sales ratio of 1.59x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue